Results of long-perm iron-chelating therapy

被引:278
作者
Gabutti, V
Piga, A
机构
[1] Paediatric Department, University of Turin
关键词
iron overload; complications; chelation; survival;
D O I
10.1159/000203853
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The improvement in survival and quality of life of iron-overloaded patients achieved by regular subcutaneous chelation has been extensively documented over the years. A review of the long-term results allows one to establish the following points: (1) with regular subcutaneous chelation, a negative iron balance can be obtained in most patients, except very young ones; (2) severe deferoxamine (DFO) toxicity may be prevented by skipping high doses and by carefully monitoring and modulating chelation, especially in patients with a low iron overload; (3) the maintenance of compliance with DFO over 0.6 and of ferritin levels below 2,000 prevents iron overload complications, at least for the first 20 years of life; (4) long-term chelation can reverse functional complications such as liver fibrosis, arrhythmia and echocardiographic abnormalities, but not complications due to extensive tissue alterations, such as frank diabetes, hypothyroidism and myocardiosclerosis; (5) intensive intravenous protocols can be successfully applied in heavily overloaded patients and represent the only possibility to reverse their dangerous iron burden in a relatively short period of time; (6) survival and quality of life in well-chelated patients are approaching a normal pattern, and (7) clinical outcome and prognosis are better evaluated by parameters that consider iron overload and chelation trends.
引用
收藏
页码:26 / 36
页数:11
相关论文
共 108 条
[71]   INSULIN RESISTANCE AND HYPERINSULINEMIA IN PATIENTS WITH THALASSEMIA MAJOR TREATED BY HYPER-TRANSFUSION [J].
MERKEL, PA ;
SIMONSON, DC ;
AMIEL, SA ;
PLEWE, G ;
SHERWIN, RS ;
PEARSON, HA ;
TAMBORLANE, WV .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (13) :809-814
[72]   SURVIVAL AND DESFERRIOXAMINE IN THALASSEMIA MAJOR [J].
MODELL, B ;
LETSKY, EA ;
FLYNN, DM ;
PETO, R ;
WEATHERALL, DJ .
BRITISH MEDICAL JOURNAL, 1982, 284 (6322) :1081-1084
[73]   TOTAL MANAGEMENT OF THALASSEMIA MAJOR [J].
MODELL, B .
ARCHIVES OF DISEASE IN CHILDHOOD, 1977, 52 (06) :489-500
[74]  
Modell B., 1984, CLIN APPROACH THALAS
[75]   LONG-TERM DESFERRIOXAMINE THERAPY IN THALASSEMIA [J].
MODELL, CB ;
BECK, J .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1974, 232 (MAY24) :201-210
[76]   THE ROLE OF IRON IN FERRITIN-MEDIATED AND HEMOSIDERIN-MEDIATED LIPID-PEROXIDATION IN LIPOSOMES [J].
OCONNELL, MJ ;
WARD, RJ ;
BAUM, H ;
PETERS, TJ .
BIOCHEMICAL JOURNAL, 1985, 229 (01) :135-139
[77]   COMPUTED-TOMOGRAPHY SCANNING OF THE LIVER TO DETERMINE EFFICACY OF IRON CHELATION-THERAPY IN THALASSEMIA MAJOR [J].
OLIVIERI, NF ;
GRISARU, D ;
DANEMAN, A ;
MARTIN, DJ ;
ROSE, V ;
FREEDMAN, MH .
JOURNAL OF PEDIATRICS, 1989, 114 (03) :427-430
[78]  
OLIVIERI NF, 1992, AM J PEDIAT HEMATOL, V14, P48
[79]   VISUAL AND AUDITORY NEUROTOXICITY IN PATIENTS RECEIVING SUBCUTANEOUS DEFEROXAMINE INFUSIONS [J].
OLIVIERI, NF ;
BUNCIC, JR ;
CHEW, E ;
GALLANT, T ;
HARRISON, RV ;
KEENAN, N ;
LOGAN, W ;
MITCHELL, D ;
RICCI, G ;
SKARF, B ;
TAYLOR, M ;
FREEDMAN, MH .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (14) :869-873
[80]   SURVIVAL IN MEDICALLY TREATED PATIENTS WITH HOMOZYGOUS BETA-THALASSEMIA [J].
OLIVIERI, NF ;
NATHAN, DG ;
MACMILLAN, JH ;
WAYNE, AS ;
LIU, PP ;
MCGEE, A ;
MARTIN, M ;
KOREN, G ;
COHEN, AR .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (09) :574-578